恩格列净对肾脏及全身血流动力学影响的随机安慰剂对照试验
该双盲安慰剂交叉试验纳入三组患者:糖尿病合并eGFR>60、糖尿病合并eGFR 20-60、非糖尿病CKD合并eGFR 20-60,分别接受恩格列净10mg每日或安慰剂4周。结果显示恩格列净在糖尿病合并CKD组降低肾血流量6%,所有组均降低GFR、血压和总血管阻力,肾血管阻力不变。
要点
- 恩格列净在糖尿病合并CKD患者中降低肾血流量6%。
- 恩格列净在所有三组中均降低GFR、血压和总血管阻力。
- 肾血管阻力未见下降,提示SGLT2i通过球前和球后联合效应保护肾小球。
核心结论
- 恩格列净在糖尿病合并CKD患者中降低肾血流量,在所有组中降低GFR、血压和总血管阻力,肾血管阻力不变,提示其通过球前和球后联合效应保护肾小球。
研究设计与样本
- 双盲安慰剂对照交叉设计,随机分配至恩格列净10mg每日或安慰剂4周,经2周洗脱后交叉至相反治疗。
- 纳入三组患者:糖尿病合并eGFR>60 ml/min per 1.73 m2(n=16)、糖尿病合并eGFR 20-60 ml/min per 1.73 m2(n=17)、非糖尿病CKD合并eGFR 20-60 ml/min per 1.73 m2(n=16)。
- 肾血流量用82铷-正电子发射断层/计算机断层测定,GFR用99m锝-二乙烯三胺五乙酸清除率测定,24小时血压和总血管阻力用Mobil-O-graph记录。
主要发现
- 与安慰剂相比,恩格列净在糖尿病合并CKD组降低肾血流量6%(P < 0.001),在糖尿病组降低4%(P = 0.29)和非糖尿病CKD组降低1%(P = 0.72),均无统计学意义。
- 恩格列净在所有组中均降低GFR、血压和总血管阻力,而肾血管阻力保持不变。
临床怎么用
- 恩格列净在糖尿病合并CKD患者中可降低肾血流量,临床使用时需关注肾功能变化。
局限性
- 样本量较小(每组16-17例),研究周期短(4周治疗加2周洗脱),可能影响结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve renal outcomes in type 2 diabetes mellitus (DM2) and chronic kidney disease (CKD). A decrease in renal blood flow (RBF) with attenuation of glomerular hyperfiltration may contribute. We examined renal and systemic hemodynamic effects of SGLT2i in relevant patient categories. METHODS: Using a double-blind placebo controlled cross-over design, we randomized patients with DM2 and estimated glomerular filtration rate (eGFR) > 60 ml/min per 1.73 m2 (n = 16), patients with DM2 and eGFR from 20 to 60 ml/min per 1.73 m2 (n = 17), and patients with nondiabetic CKD and eGFR from 20 to 60 ml/min per 1.73 m2 (n = 16) to empagliflozin 10 mg daily or placebo for 4 weeks and crossed over to the opposite treatment after 2-week washout. RBF was measured with 82Rubidium-positron emission-tomography/computed-tomography, glomerular filtration rate (GFR) with 99mTechnetium-diethylene-triamine-pentaacetate-clearance. A Mobil-O-graph was used to record 24-hour blood pressure (BP) and total vascular resistance (TVR). RESULTS: Compared to placebo, empagliflozin reduced RBF by 6% in the DM2-CKD group (P < 0.001) with nonsignificant decreases of 4% in the DM2 group and 1% in the CKD group (P = 0.29 and 0.72, respectively). Empagliflozin reduced GFR, BP, and TVR in all groups, whereas renal vascular resistance (RVR) remained unchanged. CONCLUSION: Empagliflozin reduced RBF in patients with DM2 and CKD, whereas GFR, BP, and TVR were reduced in all groups. This pattern, together with a lack of reduction in RVR, suggests SGLT2i protect the glomerulus through combined preglomerular and post glomerular effects.
引用
- Nielsen SF, Duus CL, Buus NH, et al. Randomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin. Kidney Int Rep. 2024. PMID: 39810756. doi:10.1016/j.ekir.2024.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。